|
MIV Therapeutics, a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced on March 31st, 2008 the nine month results from the first-in-man (FIM) MIVT Pilot Trial of its VESTAsync™ drug-eluting stent suggest the stent has the potential for superior safety and equivalent efficacy when compared to currently available drug-eluting stents
About MIV
|
